Previous 10 | Next 10 |
Summary Exact Sciences is shifting its focus towards achieving positive adjusted EBITDA as a way to signal a path to eliminate cash burn. The company's long-term prospects look interesting with a pipeline spread across different timelines, including a MCED test and MRD testing. Whil...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the appointment of Musa Tariq to its board of directors, effective March 6. Currently the chief marketing officer for GoFundMe, the world’s leading fundraising platform, Tariq is a distinguished marke...
The following slide deck was published by Guardant Health, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Guardant Health, Inc. 2022 Q4 - Results - Earnings Call Presentation
Guardant Health, Inc. (GH) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Alex Kleban – Vice President-Investor Relations Helmy Eltoukhy – Chairman and Co-Chief Executive Officer AmirAli Talasaz – Co-Chief Execut...
Guardant Health press release ( NASDAQ: GH ): Q4 Non-GAAP EPS of -$1.17 misses by $0.01 . Revenue of $126.9M (+17.4% Y/Y) beats by $2.97M . Expects FY 2023 revenue to be in the range of $525 million to $540 million. The consensus estimate is $554.64M. For fur...
Q4 clinical and biopharma volumes up 41% and 24% year over year Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial resul...
Guardant Health ( NASDAQ: GH ) is scheduled to announce Q4 earnings results on Thursday, February 23rd, after market close. The consensus EPS Estimate is -$1.16 (-68.1% Y/Y) and the consensus Revenue Estimate is $123.93M (+14.6% Y/Y). Over the last 2 years, GH has beaten EPS...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Citi 2023 Healthcare Services, MedTech, Tools & HCIT Conference in New York City, NY Fireside Chat on Wednesday, March 1 ...
Shield ™ blood test will be used to evaluate whether blood test option improves adherence to colorectal cancer screening recommendations in medically underserved populations at Federally Qualified Health Centers Guardant Health, Inc. (Nasdaq: GH), a leading precision onco...
Summary Despite recent data hiccups for Guardant Health, Inc., you can expect much more upsides to this stock. The flagship Guardant360 recently gained FDA approval as a companion diagnostic for the breast-cancer drug, Orsedu. Meanwhile, Guardant also formed a strategic partnership ...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...